Insufficient scRNA-seq data for expression of CYP24A1 at single-cell level.
Insufficient scRNA-seq data for expression of CYP24A1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 4995.73 | 89 / 89 | 40% | 19.46 | 363 / 901 |
bladder | 81% | 882.76 | 17 / 21 | 56% | 48.32 | 282 / 504 |
thymus | 73% | 248.37 | 474 / 653 | 42% | 9.56 | 254 / 605 |
lung | 38% | 149.00 | 218 / 578 | 63% | 52.24 | 730 / 1155 |
ureter | 0% | 0 | 0 / 0 | 100% | 111.20 | 1 / 1 |
prostate | 78% | 572.97 | 192 / 245 | 20% | 1.57 | 102 / 502 |
uterus | 26% | 84.68 | 45 / 170 | 59% | 24.78 | 270 / 459 |
esophagus | 36% | 236.76 | 524 / 1445 | 47% | 18.52 | 86 / 183 |
tonsil | 0% | 0 | 0 / 0 | 78% | 31.02 | 35 / 45 |
skin | 58% | 96.38 | 1045 / 1809 | 5% | 2.61 | 22 / 472 |
brain | 43% | 32.76 | 1130 / 2642 | 1% | 0.19 | 4 / 705 |
breast | 24% | 55.37 | 111 / 459 | 9% | 3.66 | 100 / 1118 |
pancreas | 1% | 0.15 | 2 / 328 | 21% | 9.98 | 38 / 178 |
intestine | 8% | 6.53 | 75 / 966 | 9% | 1.83 | 50 / 527 |
ovary | 3% | 1.66 | 5 / 180 | 12% | 1.49 | 53 / 430 |
stomach | 1% | 0.71 | 3 / 359 | 9% | 1.10 | 27 / 286 |
lymph node | 0% | 0 | 0 / 0 | 7% | 0.34 | 2 / 29 |
adrenal gland | 2% | 1.16 | 4 / 258 | 3% | 0.66 | 7 / 230 |
liver | 0% | 0.37 | 1 / 226 | 1% | 0.20 | 5 / 406 |
muscle | 2% | 0.75 | 13 / 803 | 0% | 0 | 0 / 0 |
heart | 1% | 1.42 | 11 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 1% | 0.09 | 1 / 80 |
adipose | 1% | 0.72 | 8 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 1% | 0.43 | 7 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 5.62 | 4 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
GO_0070561 | Biological process | vitamin D receptor signaling pathway |
GO_0006766 | Biological process | vitamin metabolic process |
GO_0042369 | Biological process | vitamin D catabolic process |
GO_0033280 | Biological process | response to vitamin D |
GO_0001649 | Biological process | osteoblast differentiation |
GO_0042359 | Biological process | vitamin D metabolic process |
GO_0005743 | Cellular component | mitochondrial inner membrane |
GO_0062181 | Molecular function | 1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity |
GO_0030342 | Molecular function | 1-alpha,25-dihydroxyvitamin D3 24-hydroxylase activity |
GO_0005506 | Molecular function | iron ion binding |
GO_0070643 | Molecular function | vitamin D 25-hydroxylase activity |
GO_0020037 | Molecular function | heme binding |
GO_0008403 | Molecular function | 25-hydroxycholecalciferol-24-hydroxylase activity |
GO_0062180 | Molecular function | 25-hydroxycholecalciferol-23-hydroxylase activity |
Gene name | CYP24A1 |
Protein name | 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (24-OHase) (Vitamin D(3) 24-hydroxylase) (EC 1.14.15.16) (Cytochrome P450 24A1) (Cytochrome P450-CC24) |
Synonyms | CYP24 |
Description | FUNCTION: A cytochrome P450 monooxygenase with a key role in vitamin D catabolism and calcium homeostasis. Via C24- and C23-oxidation pathways, catalyzes the inactivation of both the vitamin D precursor calcidiol (25-hydroxyvitamin D(3)) and the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) . With initial hydroxylation at C-24 (via C24-oxidation pathway), performs a sequential 6-step oxidation of calcitriol leading to the formation of the biliary metabolite calcitroic acid . With initial hydroxylation at C-23 (via C23-oxidation pathway), catalyzes sequential oxidation of calcidiol leading to the formation of 25(OH)D3-26,23-lactone as end product . Preferentially hydroxylates at C-25 other vitamin D active metabolites, such as CYP11A1-derived secosteroids 20S-hydroxycholecalciferol and 20S,23-dihydroxycholecalciferol . Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via FDXR/adrenodoxin reductase and FDX1/adrenodoxin . . |
Accessions | Q07973 ENST00000395954.3 [Q07973-3] ENST00000395955.7 [Q07973-2] ENST00000216862.8 [Q07973-1] |